

Table 2

Treatment Regimens Used by More Than 1 Percent of the Sarcoma Code Cohort in First- or Second-Line Therapy, in Claims Data

Regimen	Number (Percent)	
	Line 1 (n = 4,159)	Line 2 (n = 1,339)
Unclassified drugs ^a	768 (18.47)	150 (11.20)
Fluorouracil	373 (8.97)	91 (6.80)
Docetaxel + gemcitabine	284 (6.83)	64 (4.78)
Cisplatin	266 (6.40)	28 (2.09)
Carboplatin + paclitaxel	149 (3.58)	35 (2.61)
Imiquimod	145 (3.49)	48 (3.58)
Imatinib	136 (3.27)	13 (0.97)
Doxorubicin	93 (2.24)	32 (2.39)
Doxorubicin + ifosfamide	83 (2.00)	20 (1.49)
Cetuximab	79 (1.90)	28 (2.09)
Fluorouracil + oxaliplatin	67 (1.61)	8 (0.60)
Gemcitabine	65 (1.56)	35 (2.61)
Anastrozole	60 (1.44)	33 (2.46)
Cisplatin + docetaxel + fluorouracil	58 (1.39)	3 (0.22)
Carboplatin + paclitaxel + unclassified drugs ^a	56 (1.35)	11 (0.82)
Interferon alfa-2B	55 (1.32)	2 (0.15)
Tamoxifen	55 (1.32)	18 (1.34)
Letrozole	54 (1.30)	20 (1.49)
Paclitaxel	49 (1.18)	31 (2.32)
Capecitabine	47 (1.13)	25 (1.87)
Carboplatin	22 (0.53)	37 (2.76)
Liposomal doxorubicin	32 (0.77)	33 (2.46)
Pazopanib	22 (0.53)	25 (1.87)
Docetaxel + gemcitabine + unclassified drugs ^a	22 (0.53)	15 (1.12)

^a Drugs with nonspecific HCPCS codes (e.g., J3490, J3590, J9999).